Three years ago, when Pharmaceutical Executive last profiled Wendy Short Bartie, she was newly installed as senior vice ...

Consolidation to a day-to-day “Novo” name seeks consistent global recognition while retaining Novo Nordisk A/S as the legal ...

Cellectis has announced that its board of directors have approved a strategic transformation to become an in vivo gene ...

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing ...

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in ...

Specifically, patients with high cortisol levels face unique challenges that GLP-1s may not be able to tackle. Dr. Elena Christofides: We have been doing a significant amount of medical education — ...

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...

An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...

Carl Valenstein is a partner with Morgan Lewis and co-leads the firm’s Environmental, Social, and Governance (ESG) & Sustainability team. Shabeena Sharak, a summer associate with the firm, contributed ...

Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...